iRhythm Technologies, Inc. (IRTC), Interview with Kevin King, CEO Nasdaq

Posted by iRhythm Technologies on October 16, 2016


CEO Bio:
Kevin M. King has served as iRhythm’s President, Chief Executive Officer and a member of the board of directors since July 2012. Mr. King has nearly three decades of experience in the healthcare and IT industries in leadership roles. Previously, he was President, Chief Executive Officer and a Director of Affymetrix, Inc., a publicly traded technology innovator in the field of genetic analysis. Prior to that, he served as President and Chief Executive Officer of Thomson Healthcare, an information services business which focused on a range of healthcare-related businesses. Mr. King was also a senior executive at GE Healthcare, where he led several business units including Magnetic Resonance Imaging and Global Clinical Systems Business. Mr. King began his career at HP’s Medical Products Group, holding leadership roles in Sales, Marketing, R&D, and Business Development. Mr. King has a B.A. in Economics and Biology from the University of Massachusetts and an M.B.A. from New Hampshire College.

Company Description:
iRhythm is a commercial-stage digital health care company redefining the way cardiac arrhythmias are clinically diagnosed. The company combines wearable biosensor devices worn for up to 14 days and cloud-based data analytics with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. We believe improvements in arrhythmia detection and characterization have the potential to change clinical management of patients. The company’s platform, the ZIO Service, has been provided to over 500,000 patients, accumulating more than 125 million hours of curated heartbeat data within iRhythm’s data repository.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Read more

Topics: NASDAQ

Have a question?